790 related articles for article (PubMed ID: 26459027)
1. Preparation and preliminary application of monoclonal antibodies to the receptor binding region of Clostridium difficile toxin B.
Chen W; Liu WE; Li YM; Luo S; Zhong YM
Mol Med Rep; 2015 Nov; 12(5):7712-20. PubMed ID: 26459027
[TBL] [Abstract][Full Text] [Related]
2. Development of an ELISA kit using monoclonal antibody to Clostridium difficile toxin A.
Fu SW; Zhang YL; Zhou DY
World J Gastroenterol; 2004 Sep; 10(18):2747-9. PubMed ID: 15309733
[TBL] [Abstract][Full Text] [Related]
3. [Preparation and characterization of monoclonal antibody against Clostridium difficile toxin A].
Fu SW; Zhou DY; Lai ZS; Xue J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):376-8. PubMed ID: 15193243
[TBL] [Abstract][Full Text] [Related]
4. [Investigation of toxin genes of Clostridium difficile strains isolated from hospitalized patients with diarrhoea at Marmara University Hospital].
Deniz U; Ulger N; Aksu B; Karavuş M; Söyletir G
Mikrobiyol Bul; 2011 Jan; 45(1):1-10. PubMed ID: 21341153
[TBL] [Abstract][Full Text] [Related]
5. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
[TBL] [Abstract][Full Text] [Related]
6. Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA- tcdB+ C. difficile prevalent area.
Shin BM; Lee EJ; Kuak EY; Yoo SJ
Anaerobe; 2009 Dec; 15(6):266-9. PubMed ID: 19772927
[TBL] [Abstract][Full Text] [Related]
7. Production and characterization of monoclonal antibodies against vaginolysin: mapping of a region critical for its cytolytic activity.
Zvirbliene A; Pleckaityte M; Lasickiene R; Kucinskaite-Kodze I; Zvirblis G
Toxicon; 2010 Aug; 56(1):19-28. PubMed ID: 20298711
[TBL] [Abstract][Full Text] [Related]
8. Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system.
Deng XK; Nesbit LA; Morrow KJ
Clin Diagn Lab Immunol; 2003 Jul; 10(4):587-95. PubMed ID: 12853390
[TBL] [Abstract][Full Text] [Related]
9. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile.
Lemee L; Dhalluin A; Testelin S; Mattrat MA; Maillard K; Lemeland JF; Pons JL
J Clin Microbiol; 2004 Dec; 42(12):5710-4. PubMed ID: 15583303
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the premier toxin A and B assay and the TOX A/B II assay for diagnosis of Clostridium difficile infection.
Novak-Weekley SM; Hollingsworth MH
Clin Vaccine Immunol; 2008 Mar; 15(3):575-8. PubMed ID: 18175802
[TBL] [Abstract][Full Text] [Related]
11. Production and characterization of monoclonal antibodies against shope fibroma virus superoxide dismutase and glutathione-s-transferase.
Shahhosseini S; Guttikonda S; Bhatnagar P; Suresh MR
J Pharm Pharm Sci; 2006; 9(2):165-8. PubMed ID: 16959186
[TBL] [Abstract][Full Text] [Related]
12. Rapid Detection of Clostridium difficile Toxins in Stool by Raman Spectroscopy.
Koya SK; Yurgelevic S; Brusatori M; Huang C; Diebel LN; Auner GW
J Surg Res; 2019 Dec; 244():111-116. PubMed ID: 31279995
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.
Andersen KK; Strokappe NM; Hultberg A; Truusalu K; Smidt I; Mikelsaar RH; Mikelsaar M; Verrips T; Hammarström L; Marcotte H
Infect Immun; 2016 Feb; 84(2):395-406. PubMed ID: 26573738
[TBL] [Abstract][Full Text] [Related]
14. Characterization of six murine monoclonal antibodies specific for toxin B of Clostridium difficile.
Coughlin RT; Annunziato M; Roberson J; Marciani DJ
Hybridoma; 1994 Apr; 13(2):147-52. PubMed ID: 8050780
[TBL] [Abstract][Full Text] [Related]
15. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A.
Lyerly DM; Phelps CJ; Wilkins TD
J Clin Microbiol; 1985 Jan; 21(1):12-4. PubMed ID: 3968199
[TBL] [Abstract][Full Text] [Related]
17. Recombinant lipoprotein-based vaccine candidates against C. difficile infections.
Huang JH; Wu CW; Lien SP; Leng CH; Hsiao KN; Liu SJ; Chen HW; Siu LK; Chong P
J Biomed Sci; 2015 Aug; 22(1):65. PubMed ID: 26245825
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody preparation of Golgi phosphoprotein 2 and preliminary application in the early diagnosis of hepatocellular carcinoma.
Ju Q; Zhao Y; Liu Y; Zhou G; Li F; Xie P; Li Y; Li GC
Mol Med Rep; 2013 Aug; 8(2):517-22. PubMed ID: 23727927
[TBL] [Abstract][Full Text] [Related]
19. [Preparation and characterization of monoclonal antibodies against cytolethal distending toxin protein of Campylobacter jejuni].
Lu L; Shang Y; Ren F; Wang N; Jiao X; Huang J
Wei Sheng Wu Xue Bao; 2014 Aug; 54(8):950-5. PubMed ID: 25345028
[TBL] [Abstract][Full Text] [Related]
20. A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.
Zhang BZ; Cai J; Yu B; Hua Y; Lau CC; Kao RY; Sze KH; Yuen KY; Huang JD
BMC Infect Dis; 2016 Oct; 16(1):596. PubMed ID: 27770789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
